Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Rapidly Develop | Melinta Therapeutics, Allergan plc, Merck & Co.

The major market driver for growth of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market is increasing research and development activities by pharmaceutical and biopharmaceutical companies to develop new products and novel treatment. For instance, in 2017, Cempra announced promising data from the phase 3 trial of Fusidic acid for the treatment of ABSSSI. In same year, Melinta Therapeutics received US FDA for its product Baxdela, a delafloxacin based ABSSSI medicine, available in both intravenous and oral formulations. Moreover, in 2018, Fresenius Kabi received US FDA approval for new drug application of daptomycin, a lipopeptide class of antibacterial drug, in injectable form for complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactlae etc.

Get a sample copy of this report@: https://www.coherentmarketinsights.com/insight/request-sample/1531

However, growth of the ABSSSI market is expected to be hindered by increasing incidence of resistant strains of causative agents, stringent regulatory policies by government bodies, and patent expiration.

Increasing number of ambulatory patients seeking treatment for skin and skin structure infections will further propel growth of the ABSSSI market. For instance, according to article published in 2015 of PLoS One journal, skin and skin structure infections related hospital admissions were 1.6% in 2005, increased to 2.0% in 2011. Moreover, according to Decision Resource Group, in 2014, 11% of 2.7 million hospital admissions for ABSSSI were pediatric patients. The increasing pediatric patient pool is targeted by the manufacturers to enhance its product portfolio with pediatric specific products. For instance, in 2016, Allergan plc received US FDA approval for its supplemental New Drug Application (sNDA) for Teflaro, for ABSSSI indication in pediatric.

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market - Regional Analysis

Globally, acute bacterial skin and skin structure infections (ABSSSI) market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds dominate position in ABSSSI market, and this is attributed to large number of pipeline products by the regional market players. However, Asia Pacific is expected to witness fast growth, owing to increasing awareness of ABSSSI treatment and manufacturers’ geographical expansion. For instance, Basilea Pharmaceutics Ltd. signed an agreement with Shenzhen China Resources Gosun Pharmaceutical Co., in year 2017, to treat Methicillin resistant Staphylococcus aureus infection in China, Hong Kong and Macao by Basilea’s Zevtera.

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market – Competitor

Key players in the global acute bacterial skin and skin structure infections (ABSSSI) market are Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Merck & Co., Inc., Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Ltd.), Fresenius SE & Co. KGaA, Sandoz Inc. (a subsidiary of Novartis), Glenmark Pharmaceuticals Ltd, Cadila Healthcare Ltd., and Teva Pharmaceutical Industries Ltd. The ABSSSI market players are involved in strategic planning for expanding the market share of the company.

For instance, in 2014, Merck & Co., Inc. acquired Cubist Pharmaceuticals for US$ 9.5 billion. The acquisition will strengthen product portfolio by acquiring presently marketed and late stage pipeline products. Moreover, in 2017, Cempra, Inc.— a clinical-stage pharmaceutical company focused on developing treatment of infectious diseases—merged with Melinta Therapeutics, a privately held company focused on discovering, developing, and commercializing novel antibiotics to treat serious bacterial infections. The merger will commercialize the launch of Melinta’s Baxdela, a fluoroquinolone based ABSSSI treatment for susceptible bacteria.

Note: *The discount is offered on the Standard Price of the report.

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! @ https://www.coherentmarketinsights.com/insight/request-discount/1531

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market – Taxonomy

By Active Ingredient

Delafloxacin
Vancomycin
Ceftaroline fosamil
Oritavancin
Tedizolid
Daptomycin
Tigecycline
Linezolid
Others
By Route of Administration

Oral
Parenteral
Topical
By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Contact us for any query or to get a personalized report@: https://www.coherentmarketinsights.com/insight/request-customization/1531

NOTE: Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.